Prenatal endothelin or thromboxane receptor antagonism surpasses sympathoinhibition in improving cardiorenal malfunctions in preeclamptic rats

2021 ◽  
pp. 115615
Author(s):  
Yasser H. Habib ◽  
Sherien A. Abdelhady ◽  
Mennatallah A. Gowayed ◽  
Nevine M. El-Deeb ◽  
Inas E. Darwish ◽  
...  
Keyword(s):  
Receptor Antagonism ◽  
Thromboxane Receptor

Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-[3-(3-pyridinyl)propyl]octanoic acid and analogs

1992 ◽  
Vol 35 (23) ◽  
pp. 4373-4383 ◽  
Author(s):  
Shripad S. Bhagwat ◽  
Candido Gude ◽  
Clay Boswell ◽  
Nicolina Contardo ◽  
David S. Cohen ◽  
...  
Keyword(s):  
Octanoic Acid ◽  
Thromboxane Synthase ◽  
Receptor Antagonism ◽  
Thromboxane Receptor

scholarly journals Phospholipid derived mediators and glomerulonephritis

1993 ◽  
Vol 2 (2) ◽  
pp. 99-102 ◽  
Author(s):  
E. N. Wardle
Keyword(s):  
Clinical Trials ◽  
Receptor Antagonism ◽  
Thromboxane Receptor ◽  
Thromboxane Synthetase ◽  
Disease Entities

The contributions made by the various eicosanoids, PAF, the HETES and the lipoxins to the pathophysiology of glomerulonephritis is reviewed. A case can be made for clinical trials of PAF, leukotriene and thromboxane antagonists. Combined thromboxane synthetase and thromboxane receptor antagonism would seem to be the more efficacious approach for the various disease entities.

N-tert-Butyl-N′-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea, BM531, a Dual-Acting Agent for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition.

ChemInform ◽  
2003 ◽  
Vol 34 (7) ◽  
Author(s):  
Catherine Michaux ◽  
Jean-Michel Dogne ◽  
Bernadette Norberg ◽  
Francois Durant ◽  
Bernard Masereel
Keyword(s):  
Thromboxane Synthase ◽  
Receptor Antagonism ◽  
Tert Butyl ◽  
Thromboxane Receptor ◽  
Acting Agent
Sign in / Sign up

Export Citation Format

Share Document